• Home
  • Avatrombopag 20mg
  • Avatrombopag 20mg

Avatrombopag 20mg

52106

Avatrombopag is used to raise low platelet counts in adults with long-term liver disease who are due to have a medical or dental procedure.

It is also used for chronic immune thrombocytopenia when the platelet count remains low after earlier treatments.

Usual dose range: 20mg to 60mg once daily depending on the condition and platelet count; chronic liver disease procedure courses are usually 40mg or 60mg once daily for 5 days, while immune thrombocytopenia often starts at 20 mg once daily and is adjusted.

Indications vary by country and change over time; this website contains information for general patient information and should be checked against local prescribing information before clinical use.

Verification Approach: Each indication and usual dose-range sentence was drafted from at least two recognised medicines information sources, usually FDA/DailyMed or an FDA label plus EMA/eMC, MedlinePlus, Mayo Clinic, Cancer Research UK, NCI/ Cancer.gov, or another reputable medicines-information source. Doses are general adult/patient-information ranges and must not be used to prescribe or change treatment.
  • FDA/DailyMed prescribing information and FDA Oncology/Hematology approval notifications.
  • EMA and UK eMC Summary of Product
    Characteristics and patient leaflets where available.
  • NCI Cancer Drug Information/Cancer.gov and Cancer Research UK medicine information where available.
  • MedlinePlus, NHS/NICE, and other national medicines information for non-oncology or immune/respiratory medicines.
  • Peer-reviewed FDA approval summaries or manufacturer regulatory notices for very new, withdrawn, or region-specific
    indications.